Log In

Indian drugmakers set to react to better-than-feared Donald Trump executive order

Published 5 days ago2 minute read

HomeMarket NewsIndian drugmakers recover Monday's losses, rise up to 4% on better-than-feared Trump orders

Indian drugmakers recover Monday's losses, rise up to 4% on better-than-feared Trump orders

India's drugmakers, Sun Pharma Ltd. Dr. Reddy's Laboratories Ltd., Cipla Ltd. Biocon Ltd., Aurobindo Pharma Ltd., among others, most of which were underperformers during a strong day for the markets, surged as much as 4% on Tuesday, May 13, after details that emerged from the executive order that US President Donald Trump signed last evening.

Shares of Dr. Reddy's Laboratories, Divi's Laboratories, Granules India are up between 3% and 4%, while Aurobindo, Glenmark and Lupin have seen their shares surge over 2%.

As per the executive order, the Trump administration ordered drug companies to voluntarily cut prices of their drugs or face regulatory actions. The order aims to let patients buy drugs directly at the "Most-Favoured-Nation" prices.

This is because US drug prices are more than triple of the prices seen in other The Organisation for Economic Co-operation and Development (OECD) countries. Trump said that US is funding 75% of the global pharma profits, despite being under 5% of the population.

The order aims to align US drug prices with peer nations and prevent further subsidising foreign discounts through inflated domestic prices.

US drugmakers rallied on the announcements as they were not as bad as feared. The street had feared direct price cuts, which did not transpire. Pharma names like Pfizer, Eli Lilly, Amgen, Sanofi, all of them ended higher in regular trading on Wall Street.

There is also no direct fallout on US generic drug pricing due to this order.

The executive order appears to be a grab bag of drug-pricing policies that Trump’s been touting for years and involves a threat to bring the pharmaceutical industry to the negotiating table, though it’s unclear what they would need to do to prevent steep cuts.

Another factor that the street continues to watch is the potential tariffs on the sector.

After opening gap down, the Nifty Pharma and most of its index constituents recovered from the day's low. The Nifty Pharma index ended above the flat line but underperformed the strong broader market rally on Monday.

First Published: 

May 13, 2025 7:19 AM

IST

Origin:
publisher logo
CNBCTV18
Loading...
Loading...
Loading...

You may also like...